February 20, 2025

Uncategorized

New Releases from NCBI BookshelfExagamglogene Autotemcel (Casgevy): Indication: For the treatment of patients 12 years of age and older with sickle cell disease with recurrent vaso-occlusive crises: Reimbursement Recommendation [Internet].​Exagamglogene Autotemcel (Casgevy): Indication: For the treatment of patients 12 years of age and older with sickle cell disease with recurrent vaso-occlusive crises: Reimbursement Recommendation [Internet].

Leave a Comment / Uncategorized /

Canada’s Drug Agency (CDA-AMC) recommends that Casgevy be reimbursed by public drug plans for the treatment of sickle cell disease […]

Uncategorized

New Releases from NCBI BookshelfAmivantamab (Rybrevant): Indication: In combination with carboplatin and pemetrexed for the first-line treatment of adult patients with locally advanced (not amenable to curative therapy) or metastatic non-small cell lung cancer (NSCLC) with activating epidermal-growth factor receptor (EGFR) Exon 20 insertion mutations: Reimbursement Recommendation [Internet].​Amivantamab (Rybrevant): Indication: In combination with carboplatin and pemetrexed for the first-line treatment of adult patients with locally advanced (not amenable to curative therapy) or metastatic non-small cell lung cancer (NSCLC) with activating epidermal-growth factor receptor (EGFR) Exon 20 insertion mutations: Reimbursement Recommendation [Internet].

Leave a Comment / Uncategorized /

Canada’s Drug Agency (CDA-AMC) recommends that Rybrevant should be reimbursed by public drug plans when used in combination with carboplatin

Uncategorized

New Releases from NCBI BookshelfPembrolizumab (Keytruda): In combination with fluoropyrimidine and platinum–containing chemotherapy, is indicated for the first-line treatment of adult patients with locally advanced, unresectable, or metastatic HER2-negative gastric or gastroesophageal junction adenocarcinoma: Reimbursement Review [Internet].​Pembrolizumab (Keytruda): In combination with fluoropyrimidine and platinum–containing chemotherapy, is indicated for the first-line treatment of adult patients with locally advanced, unresectable, or metastatic HER2-negative gastric or gastroesophageal junction adenocarcinoma: Reimbursement Review [Internet].

Leave a Comment / Uncategorized /

Post Content ​ 

Uncategorized

New Releases from NCBI BookshelfSpesolimab (Spevigo): Indication: For the treatment of generalized pustular psoriasis (GPP) in adults and pediatric patients 12 years of age and older and weighing at least 40 kg: Reimbursement Recommendation [Internet].​Spesolimab (Spevigo): Indication: For the treatment of generalized pustular psoriasis (GPP) in adults and pediatric patients 12 years of age and older and weighing at least 40 kg: Reimbursement Recommendation [Internet].

Leave a Comment / Uncategorized /

Canada’s Drug Agency (CDA-AMC) recommends that Spevigo should be reimbursed by public drug plans for the treatment of generalized pustular

Uncategorized

New Releases from NCBI BookshelfErdafitinib (Balversa): Indication: For the treatment of adult patients with locally advanced unresectable or metastatic urothelial carcinoma harbouring susceptible FGFR3 genetic alterations who have disease progression during at least 1 line of prior therapy: Reimbursement Recommendation [Internet].​Erdafitinib (Balversa): Indication: For the treatment of adult patients with locally advanced unresectable or metastatic urothelial carcinoma harbouring susceptible FGFR3 genetic alterations who have disease progression during at least 1 line of prior therapy: Reimbursement Recommendation [Internet].

Leave a Comment / Uncategorized /

Canada’s Drug Agency (CDA-AMC) recommends that Balversa should be reimbursed by public drug plans for the treatment of locally advanced

Useful Links

NEWREDMARS SKILL AND RESEARCH        FOUNDATION

Registration No: 771800548      Contact Number : +91-8249516996

©2021-2024. Newredmars Skill and Research Foundation. All Rights Reserved.

Scroll to Top